Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Pegintron
Pegylated Interferon alpha 2b · 2 trials · 2 indications
HBeAg Loss was tested by Abbott Microparticle Enzyme Immunoassay (MEIA)
Difference in copies of HIV DNA per CD4+ T cell between baseline and week 24, assessed by Alu-HIVgag polymerase chain reaction
| Arm | Type | Description |
|---|---|---|
| PEG 1.0 mcg/kg weekly (QW) * 24 weeks | ACTIVE_COMPARATOR | PegIntron 1.0 mcg/kg weekly (QW) \* 24 weeks + 24 weeks follow-up |
| PEG 1.5 mcg/kg QW * 24 wks | EXPERIMENTAL | PegIntron 1.5 mcg/kg QW \* 24 wks + 24 wks follow-up |
| PEG 1.5 mcg/kg QW * 48 wks | EXPERIMENTAL | PegIntron 1.5 mcg/kg QW \* 48 wks + 24 wks follow-up |
| Interferon alpha | EXPERIMENTAL | pegylated Interferon alpha 2b (Pegintron) 1 µg/kg per week, 20 weeks |
| Name | Type | Description |
|---|---|---|
| pegylated interferon alpha-2b | DRUG | 1.0 mcg/kg subcutaneously (S.C.) QW for 24 weeks |
| Pegylated Interferon alpha 2b | DRUG | 1µg/kg/week |
Inclusion Criteria: * Adults with chronic hepatitis B: * Serum hepatitis B surface antigen positive for at least 6 months * Serum hepatitis B e antigen positive * Serum negative for hepatitis B surface and e antibodies * Plasma hepatitis B virus deoxyribonucleic acid (DNA) level greater th...
Pegylated interferon alpha 2b is an investigational exogenous protein developed by Merck & Company, Inc. (MRK). It is being studied in infectious disease, specifically for HIV-1 infection and chronic hepatitis B. The drug is in Phase 2 clinical development.
Pegylated interferon alpha 2b is being studied for the treatment of HIV-1 infection and chronic hepatitis B. It is not yet approved for any indication and remains in clinical development.
Pegylated interferon alpha 2b targets F8, an exogenous protein. This target is associated with the drug's mechanism of action in infectious disease.
Pegylated interferon alpha 2b is developed by Merck & Company, Inc., which trades under the ticker MRK.
Pegylated interferon alpha 2b is in Phase 2 clinical development. It is investigational and has not been approved by the FDA for any indication.
Pegylated interferon alpha 2b has been studied in two completed trials: NCT01935089, a Phase 2 pilot trial in HIV-1 infection with 20 participants, and NCT00536263, a Phase 3 trial in chronic hepatitis B with 671 participants.